GI
BTAI icon

Gradient Investments’s BioXcel Therapeutics BTAI Stock Holding History

Gradient Investments’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-9
Closed -$6K – 1155
2021
Q1 		$6K Buy
+9
New +$7.24K ﹤0.01% 848

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AS
Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Gradient Investments's BTAI Position: Q2 2021 in Review

Gradient Investments sold out of BioXcel Therapeutics (BTAI) in Q2 2021, closing a stake of 9 shares — an estimated $6K sold.

Gradient Investments first reported a position in BTAI in Q1 2021 and held it in 1 quarter. The position peaked at $6K in Q1 2021. 108 funds tracked by Wall St. Rank hold BTAI as of Q2 2021.

  • Gradient Investments reported no remaining BioXcel Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Gradient Investments sold 9 BioXcel Therapeutics shares in Q2 2021, an estimated $6K.
  • Gradient Investments first reported a position in BioXcel Therapeutics in Q1 2021 and held it in 1 quarter.
  • Gradient Investments's BioXcel Therapeutics position peaked at $6K in Q1 2021.
  • 108 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2021.

Based on Gradient Investments's 13F filing for Q2 2021, filed 12 Jul 2021.